{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:36:39Z","timestamp":1783528599081,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004844","name":"National Cheng Kung University Hospital","doi-asserted-by":"publisher","award":["NCKUH-11504005"],"award-info":[{"award-number":["NCKUH-11504005"]}],"id":[{"id":"10.13039\/501100004844","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bempedoic acid is an oral cholesterol-lowering medication used to reduce low-density lipoprotein cholesterol (LDL-C), particularly in patients who require additional lipid lowering. Clinical trials have shown that bempedoic acid increases serum uric acid levels, but the implications of this effect in real-world clinical practice, including the need for anti-gout treatment, are not well defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using a large, multi-institutional U.S. electronic health record database. Adult patients with hyperlipidemia who have newly initiated bempedoic acid were compared with those initiating ezetimibe. Propensity score matching was used to balance baseline characteristics, yielding 7676 patients in each group. The primary outcome was incident hyperuricemia, defined as serum uric acid &gt;7.0\u2009mg\/dL. A secondary outcome was initiation of anti-gout therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During 12 months of follow-up, hyperuricemia occurs more frequently in patients treated with bempedoic acid than in those receiving ezetimibe (hazard ratio [HR] 1.94; 95% confidence interval [CI] 1.58\u20132.37; p\u2009=\u20090.008). In contrast, initiation of anti-gout therapy does not differ between groups (HR 1.06; 95% CI 0.86\u20131.29; p\u2009=\u20090.59). Longitudinal changes in lipid parameters, inflammatory markers, and glycemic measures are generally similar between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In real-world clinical practice, bempedoic acid use is associated with a higher incidence of laboratory-defined hyperuricemia compared with ezetimibe, but this increase does not translate into greater use of anti-gout medications. These findings support the continued use of bempedoic acid for additional LDL-C lowering, with awareness of its effect on serum uric acid.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-026-01545-2","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:53:54Z","timestamp":1775019234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hyperuricemia risk in bempedoic acid-treated hyperlipidemic patients"],"prefix":"10.1038","volume":"6","author":[{"given":"Po-Hsueh","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2841-0338","authenticated-orcid":false,"given":"Daniel Hsiang-Te","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki Hsing-Chun","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharmaraj","family":"Vairaperumal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward Chia-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3643-5204","authenticated-orcid":false,"given":"Ping-Yen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"1545_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pop.2012.11.003","volume":"40","author":"RH Nelson","year":"2013","unstructured":"Nelson, R. H. Hyperlipidemia as a Risk Factor for Cardiovascular Disease. Prim. Care: Clin. Off. Pract. 40, 195\u2013211 (2013).","journal-title":"Prim. Care: Clin. Off. Pract."},{"key":"1545_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11892-019-1178-6","volume":"19","author":"PD Rosenblit","year":"2019","unstructured":"Rosenblit, P. D. Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition. Curr. Diab Rep. 19, 61 (2019).","journal-title":"Curr. Diab Rep."},{"key":"1545_CR3","doi-asserted-by":"crossref","unstructured":"Wilson, P. W. F. et al. Systematic Review for the 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139, (2019).","DOI":"10.1161\/CIR.0000000000000626"},{"key":"1545_CR4","first-page":"166","volume":"41","author":"PY Liu","year":"2025","unstructured":"Liu, P. Y. Reappraisal of the New Clinical Pathway National Consensus on Lipid Profile in Taiwan 2025: Where Do We Stand Now? Acta Cardiol Sin. 41, 166\u2013168 (2025).","journal-title":"Acta Cardiol Sin."},{"key":"1545_CR5","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes, E. S. et al. Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J. 36, 1012\u20131022 (2015).","journal-title":"Eur. Heart J."},{"key":"1545_CR6","doi-asserted-by":"crossref","unstructured":"Di Minno, A. et al. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia: Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Am. Heart Assoc. 9, e016262 (2020).","DOI":"10.1161\/JAHA.119.016262"},{"key":"1545_CR7","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","volume":"46","author":"F Mach","year":"2025","unstructured":"Mach, F. et al. ESC\/EAS Scientific Document Group. 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur. Heart J. 46, 4359\u20134378 (2025).","journal-title":"Eur. Heart J."},{"key":"1545_CR8","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"KK Ray","year":"2019","unstructured":"Ray, K. K. et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N. Engl. J. Med. 380, 1022\u20131032 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1545_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jjcc.2024.03.006","volume":"84","author":"SNS Yarrarapu","year":"2024","unstructured":"Yarrarapu, S. N. S. et al. Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid. J. Cardiol. 84, 22\u201329 (2024).","journal-title":"J. Cardiol."},{"key":"1545_CR10","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen, S. E. et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N. Engl. J. Med. 388, 1353\u20131364 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1545_CR11","doi-asserted-by":"crossref","unstructured":"Laufs, U. et al. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. J. Am. Heart Assoc. 8, e011662 (2019).","DOI":"10.1161\/JAHA.118.011662"},{"key":"1545_CR12","doi-asserted-by":"crossref","unstructured":"Biolo, G. et al. Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome. Front. Cardiovasc. Med. 9, 1028355 (2022).","DOI":"10.3389\/fcvm.2022.1028355"},{"key":"1545_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette, P. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis. 76, 29\u201342 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1545_CR14","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2174\/1381612825666190408122557","volume":"25","author":"S Zhang","year":"2019","unstructured":"Zhang, S. et al. Hyperuricemia and Cardiovascular Disease. Curr. Pharm. Des. 25, 700\u2013709 (2019).","journal-title":"Curr. Pharm. Des."},{"key":"1545_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/0002-9149(92)90671-K","volume":"69","author":"RB D\u2019Agostino","year":"1992","unstructured":"D\u2019Agostino, R. B., Kannel, W. B., Stepanians, M. N. & D\u2019Agostino, L. C. A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia. Am. J. Cardiol. 69, 28\u201334 (1992).","journal-title":"Am. J. Cardiol."},{"key":"1545_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.pcad.2004.04.007","volume":"47","author":"MH Davidson","year":"2004","unstructured":"Davidson, M. H. & Toth, P. P. Comparative effects of lipid-lowering therapies. Prog. Cardiovasc Dis. 47, 73\u2013104 (2004).","journal-title":"Prog. Cardiovasc Dis."},{"key":"1545_CR17","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.mayocp.2022.02.027","volume":"97","author":"N Leung","year":"2022","unstructured":"Leung, N., Yip, K., Pillinger, M. H. & Toprover, M. Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications. Mayo Clin. Proc. 97, 1345\u20131362 (2022).","journal-title":"Mayo Clin. Proc."},{"key":"1545_CR18","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s10557-021-07147-5","volume":"35","author":"CM Ballantyne","year":"2021","unstructured":"Ballantyne, C. M. et al. Role of Bempedoic Acid in Clinical Practice. Cardiovasc Drugs Ther. 35, 853\u2013864 (2021).","journal-title":"Cardiovasc Drugs Ther."},{"key":"1545_CR19","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12933-023-02022-z","volume":"22","author":"O De Filippo","year":"2023","unstructured":"De Filippo, O. et al. Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials. Cardiovasc Diabetol. 22, 324 (2023).","journal-title":"Cardiovasc Diabetol."},{"key":"1545_CR20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.amjcard.2020.06.028","volume":"131","author":"MU Khan","year":"2020","unstructured":"Khan, M. U., Khan, M. Z., Munir, M. B., Balla, S. & Khan, S. U. Meta-analysis of the Safety and Efficacy of Bempedoic Acid. Am. J. Cardiol. 131, 130\u2013132 (2020).","journal-title":"Am. J. Cardiol."},{"key":"1545_CR21","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald, J. D. et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken) 72, 744\u2013760 (2020).","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1545_CR22","volume":"4","author":"KK Ray","year":"2025","unstructured":"Ray, K. K. et al. Association of Uric Acid-Lowering Therapies on Gout Frequency with Bempedoic Acid. Clin. Insights CLEAR Outcomes JACC Adv. 4, 102207 (2025).","journal-title":"Clin. Insights CLEAR Outcomes JACC Adv."},{"key":"1545_CR23","doi-asserted-by":"publisher","unstructured":"Wang, X. et al. Novel insights into post-marketing AEs associated with bempedoic acid: a comprehensive analysis utilizing the FAERS database. Expert Opin. Drug Saf. 1\u20138. https:\/\/doi.org\/10.1080\/14740338.2025.2468868. Online ahead of print. (2025).","DOI":"10.1080\/14740338.2025.2468868"},{"key":"1545_CR24","doi-asserted-by":"publisher","first-page":"030502","DOI":"10.11613\/BM.2025.030502","volume":"35","author":"J Wang","year":"2025","unstructured":"Wang, J., Tsai, K. W., Lu, C. L. & Lu, K. C. Analyzing clinical laboratory data outcomes in retrospective cohort studies using TriNetX. Biochem. Med. (Zagreb) 35, 030502 (2025).","journal-title":"Biochem. Med. (Zagreb)"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01545-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01545-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01545-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T23:05:04Z","timestamp":1780873504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01545-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1545"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01545-2","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the authors listed consent to the submission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"328"}}